TITLE

Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation

AUTHOR(S)
Porter, Corrine J.; Matthews, Jacqueline M.; Mackay, Joel P.; Pursglove, Sharon E.; Schmidberger, Jason W.; Leedman, Peter J.; Pero, Stephanie C.; Krag, David N.; Wilce, Matthew C. J.; Wilce, Jacqueline A
PUB. DATE
January 2007
SOURCE
BMC Structural Biology;2007, Vol. 7, p58
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Human growth factor receptor bound protein 7 (Grb7) is an adapter protein that mediates the coupling of tyrosine kinases with their downstream signaling pathways. Grb7 is frequently overexpressed in invasive and metastatic human cancers and is implicated in cancer progression via its interaction with the ErbB2 receptor and focal adhesion kinase (FAK) that play critical roles in cell proliferation and migration. It is thus a prime target for the development of novel anti-cancer therapies. Recently, an inhibitory peptide (G7-18NATE) has been developed which binds specifically to the Grb7 SH2 domain and is able to attenuate cancer cell proliferation and migration in various cancer cell lines. Results: As a first step towards understanding how Grb7 may be inhibited by G7-18NATE, we solved the crystal structure of the Grb7 SH2 domain to 2.1 Å resolution. We describe the details of the peptide binding site underlying target specificity, as well as the dimer interface of Grb 7 SH2. Dimer formation of Grb7 was determined to be in the µM range using analytical ultracentrifugation for both full-length Grb7 and the SH2 domain alone, suggesting the SH2 domain forms the basis of a physiological dimer. ITC measurements of the interaction of the G7-18NATE peptide with the Grb7 SH2 domain revealed that it binds with a binding affinity of Kd = ∼35.7 µM and NMR spectroscopy titration experiments revealed that peptide binding causes perturbations to both the ligand binding surface of the Grb7 SH2 domain as well as to the dimer interface, suggesting that dimerisation of Grb7 is impacted on by peptide binding. Conclusion: Together the data allow us to propose a model of the Grb7 SH2 domain/G7-18NATE interaction and to rationalize the basis for the observed binding specificity and affinity. We propose that the current study will assist with the development of second generation Grb7 SH2 domain inhibitors, potentially leading to novel inhibitors of cancer cell migration and invasion.
ACCESSION #
35110906

 

Related Articles

  • The PML isoform IV is a negative regulator of nuclear EGFR’s transcriptional activity in lung cancer. Kuo, Hong-Yi; Chen, Yi-Chen; Chang, Hsiang-Yi; Jeng, Jen-Chong; Lin, Erh-Hsuan; Pan, Chih-Ming; Chang, Yu-Wei; Wang, Mong-Lien; Chou, Yu-Ting; Shih, Hsiu-Ming; Wu, Cheng-Wen // Carcinogenesis;Aug2013, Vol. 34 Issue 8, p1708 

    Epidermal growth factor receptor (EGFR) is a membrane-bound receptor tyrosine kinase, which can transduce intracellular signals responsible for cell proliferation. It is frequently overexpressed and/or constitutively activated in non-small cell lung cancer and thus is considered as a major cause...

  • Review of Clinic Trials: Agents Targeting c-Met. Abidoye, Oyewale; Murukurthy, Nadh; Salgia, Ravi // Reviews on Recent Clinical Trials;May2007, Vol. 2 Issue 2, p143 

    Receptor tyrosine kinases are a group of molecules that can enhance cellular proliferation, cell motility and migration, and eventual metastasis. c-Met receptor tyrosine kinase has a significant biological and biochemical effect on cancer cells, and appears to be an important therapeutic target....

  • Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. Andersson, Mattias K.; Åman, Pierre // Cancer Cell International;2008, Vol. 8, Special section p1 

    Background: Tyrosine kinase inhibitors (TKIs) have gained much attention in recent years as targeted agents for the treatment of a wide range of human cancers. We have investigated the effect of the TKIs gefitinib and vandetanib on tumor cell lines derived from Ewing sarcoma, a highly malignant...

  • The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Sheng, Q.; Liu, J. // British Journal of Cancer;4/12/2011, Vol. 104 Issue 8, p1241 

    The epithelial growth factor receptor (EGFR) family of receptor tyrosine kinases has been reported to have an active role in a number of malignancies. Amplifications and overexpression of various EGFR family members, including EGFR, Her2, and ErbB3, have been reported in epithelial ovarian...

  • Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Wenle Xia; Mullin, Robert J.; Keith, Barry R.; Lei-Hua Liu; Hong Ma; Rusnak, David W.; Owens, Gary; Alligood, Krystal J.; Spector, Neil L. // Oncogene;9/12/2002, Vol. 21 Issue 41, p6255 

    Presents a study which examined the anti-tumor activity of the GW572016 molecule. Inhibition of epidermal growth factor receptor erbB2 tyrosine kinases; Inhibition of the activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival; Materials and methods; Results and...

  • Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity. Naruo, Yoshimi; Nagashima, Takeshi; Ushikoshi-Nakayama, Ryoko; Saeki, Yuko; Nakakuki, Takashi; Naka, Takashi; Tanaka, Hiroshi; Shih-Feng Tsai; Okada-Hatakeyama, Mariko // BMC Systems Biology;2011, Vol. 5 Issue 1, p29 

    Background: Epidermal growth factor receptor (EGFR) signaling plays an important role in the regulation of cell proliferation, survival, metastasis, and invasion in various tumors. Earlier studies showed that the EGFR is frequently overexpressed in non-small-cell lung cancer (NSCLC) and EGFR...

  • E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion.  // BMC Cancer;2011, Vol. 11 Issue 1, p309 

    The article presents information on a study which focuses on the role of orally active multi-targeted tyrosine kinase inhibitor E7080 in preventing tumor angiogenesis and invasion. The study analyzed the effect of E7080 on cell proliferation, migration and invasion, and also measured inhibition...

  • Modulating the Structure of EGFR with UV Light: New Possibilities in Cancer Therapy. Correia, Manuel; Thiagarajan, Viruthachalam; Coutinho, Isabel; Gajula, Gnana Prakash; Petersen, Steffen B.; Neves-Petersen, Maria Teresa // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor tyrosine kinases. EGFR is activated upon binding to e.g. epidermal growth factor (EGF), leading to cell survival, proliferation and migration. EGFR overactivation is associated with tumor progression. We have...

  • Targeted Blockage of Signal Transducer and Activator of Transcription 5 Signaling Pathway with Decoy Oligodeoxynucleotides Suppresses Leukemic K562 Cell Growth. Wang, Xiaozhong; Zeng, Jianming; Shi, Mei; Zhao, Shiqiao; Bai, Weijun; Cao, Weixi; Tu, Zhiguang; Huang, Zonggan; Feng, Wenli // DNA & Cell Biology;Feb2011, Vol. 30 Issue 2, p71 

    The protein signal transducer and activator of transcription 5 (STAT5) of the JAK/STAT pathway is constitutively activated because of its phosphorylation by tyrosine kinase activity of fusion protein BCR-ABL in chronic myelogenous leukemia (CML) cells. This study investigated the potential...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics